中美地缘政治高度不确定性的扰动背景下,远大医药近6个交易日累计上涨近40%,无惧行业波动。值得注意的是,国际大行中金在5月13日上调目标价20.0%至9.6港币,这是中金年内第三次上调远大医药的目标价。大涨背后是远大医药密集的创新进展等积极消息的释放,包括:脓毒症创新药STC3141的二期临床成功、创新核素偶联药物TLX591加入国际多中心三期申请获受理、诊断RDC产品TLX591-CDx完成三期...
Source Link中美地缘政治高度不确定性的扰动背景下,远大医药近6个交易日累计上涨近40%,无惧行业波动。值得注意的是,国际大行中金在5月13日上调目标价20.0%至9.6港币,这是中金年内第三次上调远大医药的目标价。大涨背后是远大医药密集的创新进展等积极消息的释放,包括:脓毒症创新药STC3141的二期临床成功、创新核素偶联药物TLX591加入国际多中心三期申请获受理、诊断RDC产品TLX591-CDx完成三期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.